PHARMACOGENETIC PREDICTORS OF SEVERE CHRONIC PERIPHERAL NEUROPATHY IN STAGE II-III COLON CANCER (CC) PATIENTS TREATED WITH OXALIPLATIN-BASED ADJUVANT CHEMOTHERAPY (CT). A GEMCAD STUDY

被引：0
|
作者：
Custodio, A. [1 ]
Moreno, J. [1 ]
Aparicio, J. [2 ]
Gallego Plazas, J. [3 ]
Fernandez Martos, C. [4 ]
Maurel, J. [5 ]
Ramos, D. [6 ]
Cejas, P. [1 ]
Madero, R. [7 ]
Feliu, J. [1 ]
机构：
[1] La Paz Univ Hosp, Madrid, Spain
[2] La Fe Univ Hosp, Med Oncol Dept, Valencia, Spain
[3] Elche Univ Hosp, Med Oncol Dept, Elche, Spain
[4] Fdn Inst Valenciano Oncol, Med Oncol Dept, Valencia, Spain
[5] Hosp Clin Barcelona, Barcelona, Spain
[6] La Fe Univ Hosp, Dept Pathol, Valencia, Spain
[7] La Paz Univ Hosp, Biostat Unit, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [31] Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer
    Akagunduz, Baran
    Guven, Deniz Can
    Ozer, Muhammet
    Okten, Ilker Nihat
    Atag, Elif
    Unek, Ilkay Tugba
    Tatli, Ali Murat
    Karaoglu, Aziz
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (02)
  • [32] The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
    Leen Liao
    Jinghua Tang
    Zhigang Hong
    Wu Jiang
    Yuan Li
    Lingheng Kong
    Kai Han
    Zhenlin Hou
    Chenzhi Zhang
    Chi Zhou
    Linjie Zhang
    Qiaoqi Sui
    Binyi Xiao
    Weijian Mei
    Jiehai Yu
    Wanjun Yang
    Zhizhong Pan
    Pei-Rong Ding
    [J]. BMC Cancer, 24
  • [33] The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
    Liao, Leen
    Tang, Jinghua
    Hong, Zhigang
    Jiang, Wu
    Li, Yuan
    Kong, Lingheng
    Han, Kai
    Hou, Zhenlin
    Zhang, Chenzhi
    Zhou, Chi
    Zhang, Linjie
    Sui, Qiaoqi
    Xiao, Binyi
    Mei, Weijian
    Yu, Jiehai
    Yang, Wanjun
    Pan, Zhizhong
    Ding, Pei-Rong
    [J]. BMC CANCER, 2024, 24 (01)
  • [34] Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy
    Sun, Xicai
    Yuan, Wei
    Hao, Furong
    Zhuang, Wenzhen
    [J]. MEDICAL SCIENCE MONITOR, 2017, 23 : 5389 - 5395
  • [35] Baseline creatinine clearance as an indicator of severe adverse events associated with oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer: Safety analysis of the phase III Japanese ACHIEVE trial
    Nakamura, Masato
    Kotaka, Masahito
    Eto, Tetsuya
    Manaka, Dai
    Hasegawa, Junichi
    Takagane, Akinori
    Kato, Takeshi
    Munemoto, Yoshinori
    Nakamura, Fumitaka
    Bando, Hiroyuki
    Taniguchi, Hiroki
    Gamoh, Makio
    Shiozawa, Manabu
    Yamanaka, Takeharu
    Mizushima, Tsunekazu
    Sakamoto, Junichi
    Saji, Shigetoyo
    Ohtsu, Atsushi
    Mori, Masaki
    Yoshino, Takayuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [36] Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.
    Andre, Thierry
    Bonnetain, Franck
    Mineur, Laurent
    Bennouna, Jaafar
    Desrame, Jerome
    Faroux, Roger
    Dauba, Jerome
    Vernerey, Dewi
    Aissat, Nasredine
    Louvet, Christophe
    Lepere, Celine
    Dupuis, Olivier Jean Marie
    Becouarn, Yves
    Mabro, May
    Egreteau, Joelle
    Bouche, Olivier
    Deplanque, Gael
    Ychou, Marc
    De Gramont, Aimery
    Taieb, Julien
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Real-world tolerance and outcomes to oxaliplatin-based adjuvant chemotherapy for stage III colon cancer - Does dose intensity matter?
    Yoon, Robert
    Wilkinson, Kate
    Gabriel, Gabriel
    Kaadan, Nasreen
    Roberts, Tara
    Lim, Stephanie
    Ray, Asghari
    Lee, Cheok Soon
    Chua, Wei
    Ng, Weng
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 132 - 133
  • [38] Longitudinal effects of adjuvant chemotherapy and related neuropathy on HU in stage II and III colon cancer patients: A prospective cohort study
    Jongeneel, Gabrielle
    Greuter, Marjolein J. E.
    van Erning, Felice N.
    Twisk, Jos W. R.
    Koopman, Miriam
    Punt, Cornelis J. A.
    Vink, Geraldine R.
    Coupe, Veerle M. H.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (11) : 2702 - 2711
  • [39] A comparison of oxaliplatin-based adjuvant chemotherapy versus improved nodal sampling for stage II colon cancer: Cost-effectiveness and survival
    Chen, SL
    Sim, MS
    Bilchik, AJ
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 41 - 42
  • [40] p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Oh, Hyeon Jeong
    Bae, Jeong Mo
    Wen, Xianyu
    Jung, Seorin
    Kim, Younghoon
    Kim, Kyung Ju
    Cho, Nam-Yun
    Kim, Jung Ho
    Han, Sae-Won
    Kim, Tae-You
    Kang, Gyeong Hoon
    [J]. BRITISH JOURNAL OF CANCER, 2019, 120 (08) : 797 - 805
12345